Inhaled therapies in cystic fibrosis (Q46275410)

21 December 2017

review article

1 reference

title

Inhaled therapies in cystic fibrosis (English)

1 reference

21 December 2017

0 references

Dubus JC

1

1 reference

21 December 2017

Ravilly S

series ordinal

2

1 reference

21 December 2017

publication date

1 October 2008

1 reference

21 December 2017

number of pages

10

1 reference

Revue des Maladies Respiratoires

inferred from page(s)

published in

1 reference

21 December 2017

volume

25

1 reference

21 December 2017

issue

8

1 reference

21 December 2017

page(s)

989-998

1 reference

21 December 2017

RhDNase I aerosol deposition and related factors in cystic fibrosis

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

The influence of age on aerosol deposition in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Liquid atomizing: nebulizing and other methods of producing aerosols

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Lung deposition after electronically breath-controlled inhalation and manually triggered conventional inhalation in cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

[Aerosol: present and future]

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older.

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

A multi-method assessment of treatment adherence for children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Nebulised dornase alpha: adherence in adults with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Educational practice for inhaled treatments in French cystic fibrosis care centers.

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Hyperosmolar agents and clearance of mucus in the diseased airway

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Dornase alfa reduces air trapping in children with mild cystic fibrosis lung disease: a quantitative analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Recombinant human DNase nebulisation in children with cystic fibrosis: before bedtime or after waking up?

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Inhaled mannitol in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Inhaled mannitol improves lung function in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Safety assessment of inhaled xylitol in subjects with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Unfractionated heparin reduces the elasticity of sputum from patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Lung delivery of aerosolized dextran.

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Dry powder versus intravenous and nebulized gentamicin in cystic fibrosis and bronchiectasis. A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Inhaled azithromycin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Nebulisers comparison with inhaled tobramycin in young children with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Use of aerosolized colistin sodium in cystic fibrosis patients awaiting lung transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Nebulization and anti-Pseudomonas aeruginosa activity of colistin

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Effect of salmeterol on Pseudomonas aeruginosa infection of respiratory mucosa

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Inhaled corticosteroids for cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Multicenter Randomized Controlled Trial of Withdrawal of Inhaled Corticosteroids in Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Deposition and expression of aerosolized rAAV vectors in the lungs of Rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Gene therapy for cystic fibrosis with aerosolized adenovirus-CFTR: characterization of the aerosol and scintigraphic determination of lung deposition in baboons

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

French multicenter randomized double-blind placebo-controlled trial on nebulized amiloride in cystic fibrosis patients. The Amiloride-AFLM Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Pulmonary deposition of nebulised amiloride in cystic fibrosis: comparison of two nebulisers

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Nano-liposomal dry powder inhaler of Amiloride Hydrochloride.

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Inhaled L-arginine improves exhaled nitric oxide and pulmonary function in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Aerosol α1 -antitrypsin treatment for cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

A Randomized Trial of Inhaled Cyclosporine in Lung-Transplant Recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Nebulized drug admixtures: effect on aerosol characteristics and albuterol output.

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

Inhalation solutions: which one are allowed to be mixed? Physico-chemical compatibility of drug solutions in nebulizers

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

[Disinfection of devices for nebulization: stakes, difficulties, and improvement proposals]

1 reference

https://api.crossref.org/works/10.1016%2FS0761-8425%2808%2974415-2

7 January 2021

10.1016/S0761-8425(08)74415-2

Identifiers

DOI

1 reference

21 December 2017

PubMed ID

18971805

1 reference

21 December 2017